Short- and long-term antihypertensive effect of egg protein-derived peptide QIGLF.
BACKGROUND
The present study aimed to investigate the in vivo antihypertensive effect on spontaneously hypertensive rats (SHRs) induced by egg protein-derived peptide QIGLF, which has been previously characterized in vitro as a potent angiotensin-converting enzyme inhibitor.


RESULTS
In vivo antihypertensive effect of QIGLF orally administered was evaluated by the tail-cuff method. The systolic blood pressure and the diastolic blood pressure of rats were measured 0, 5, 10, 15 and 20 h after administration every day. Subsequently, the effect of QIGLF on angiotensin-converting enzyme mRNA expression in the kidney of SHRs was evaluated by a polymerase chain reaction. Systolic blood pressure was found to be reduced markedly in the SHRs after a single oral administration.


CONCLUSIONS
The results show that the effect of QIGLF (50 mg kg-1body weight) was similar to that of captopril (10 mg kg-1body weight) with respect to lowering systolic blood pressure in SHRs. Therefore, egg white protein-derived peptide QIGLF may be useful in the prevention or treatment of hypertension. © 2016 Society of Chemical Industry.
College of Food Science and Engineering, Bohai University, Jinzhou, 121013, P.R. China.|Department of Food, Nutrition and Packaging Sciences, Clemson University, Clemson, SC 29634, USA.
Zhipeng
Z
Yu
College of Food Science and Engineering, Bohai University, Jinzhou, 121013, P.R. China.
Wenzhu
W
Zhao
Laboratory of Nutrition and Functional Food, Jilin University, Changchun, 130062, P.R. China.
Long
L
Ding
Department of Food, Nutrition and Packaging Sciences, Clemson University, Clemson, SC 29634, USA.
Yaqi
Y
Wang
Department of Food, Nutrition and Packaging Sciences, Clemson University, Clemson, SC 29634, USA.
Feng
F
Chen
Laboratory of Nutrition and Functional Food, Jilin University, Changchun, 130062, P.R. China.
Jingbo
J
Liu
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000009:adverse effects / Q000627:therapeutic use; D019587:Dietary Supplements / Q000009:adverse effects; D004527:Egg Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004794:Enzyme Repression; D006973:Hypertension / Q000178:diet therapy* / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D007668:Kidney / Q000378:metabolism / Q000503:physiopathology*; D008297:Male; D009842:Oligopeptides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010446:Peptide Fragments / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007703:Peptidyl-Dipeptidase A / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D011918:Rats, Inbred SHR; D017208:Rats, Wistar; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D004527:Egg Proteins; D009842:Oligopeptides; D010446:Peptide Fragments; D012333:RNA, Messenger; C561682:glutaminyl-isoleucyl-glycyl-leucyl-phenylalanine; D002216:Captopril; D007703:Peptidyl-Dipeptidase A
angiotensin- converting enzyme; antihypertensive effect; egg white; peptide; protein; spontaneously hypertensive rats